A detailed history of Black Rock Inc. transactions in Unicycive Therapeutics, Inc. stock. As of the latest transaction made, Black Rock Inc. holds 51,837 shares of UNCY stock, worth $23,326. This represents 0.0% of its overall portfolio holdings.

Number of Shares
51,837
Holding current value
$23,326
% of portfolio
0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

BUY
$0.4 - $1.46 $20,734 - $75,682
51,837 New
51,837 $25,000
Q2 2022

Aug 12, 2022

SELL
$0.7 - $1.33 $16,916 - $32,140
-24,166 Closed
0 $0
Q1 2022

May 12, 2022

BUY
$1.07 - $2.28 $8,689 - $18,515
8,121 Added 50.61%
24,166 $31,000
Q4 2021

Feb 10, 2022

BUY
$1.81 - $3.05 $8,329 - $14,036
4,602 Added 40.22%
16,045 $33,000
Q3 2021

Nov 09, 2021

BUY
$2.47 - $5.85 $28,264 - $66,941
11,443 New
11,443 $33,000

Others Institutions Holding UNCY

About Unicycive Therapeutics, Inc.


  • Ticker UNCY
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 15,052,500
  • Market Cap $6.77M
  • Description
  • Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease; and UNI 494, for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Al...
More about UNCY
Track This Portfolio

Track Black Rock Inc. Portfolio

Follow Black Rock Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

News

Stay updated on Black Rock Inc. with notifications on news.